Valeant gets extra month from lenders to file annual report
Canadian pharma company says it remains well positioned to meet its obligations
Shake-up at Valeant signals stunning fall from grace for J Michael Pearson
Pharmaceutical giant faces a growing list of questions from investors and regulators
Joe Nocera: Valeant Pharmaceuticals looking like another Enron
Eye-popping growth and questionable acquisitions raise far too many questions
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices